Eversept Partners LP Has $53.70 Million Stake in Vaxcyte, Inc. $PCVX

Eversept Partners LP lessened its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 22.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 924,193 shares of the company’s stock after selling 273,529 shares during the period. Vaxcyte comprises 2.8% of Eversept Partners LP’s investment portfolio, making the stock its 8th biggest holding. Eversept Partners LP’s holdings in Vaxcyte were worth $53,705,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PCVX. Maverick Capital Ltd. increased its holdings in Vaxcyte by 1.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,377,738 shares of the company’s stock worth $80,060,000 after purchasing an additional 23,501 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of Vaxcyte by 48.7% in the first quarter. Quantinno Capital Management LP now owns 21,563 shares of the company’s stock worth $1,253,000 after purchasing an additional 7,062 shares during the last quarter. First Light Asset Management LLC bought a new position in shares of Vaxcyte in the first quarter valued at approximately $8,239,000. SummitTX Capital L.P. lifted its holdings in shares of Vaxcyte by 403.3% in the first quarter. SummitTX Capital L.P. now owns 74,842 shares of the company’s stock valued at $4,349,000 after purchasing an additional 59,973 shares in the last quarter. Finally, Inceptionr LLC purchased a new position in shares of Vaxcyte during the first quarter valued at approximately $334,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the subject of several recent research reports. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $86.00.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $55.23, for a total value of $110,460.00. Following the transaction, the chief executive officer owned 134,215 shares of the company’s stock, valued at approximately $7,412,694.45. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $56.33, for a total value of $126,742.50. Following the completion of the transaction, the chief operating officer owned 156,760 shares of the company’s stock, valued at $8,830,290.80. This trade represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 75,448 shares of company stock valued at $4,091,197. 3.30% of the stock is owned by insiders.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $55.50 on Tuesday. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The firm has a 50-day moving average price of $52.71 and a two-hundred day moving average price of $54.71.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the company earned ($1.04) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.